**Conflict of interest:** All authors declare no competing financial interest.

Introduction {#ijc32079-sec-0003}
============

Colorectal cancer is one of the most common digestive system malignant tumors that endangers human health in the world. The incidence of colorectal cancer has obvious regional and ethnic differences and is significantly higher in the United States than in Asia.[1](#ijc32079-bib-0001){ref-type="ref"} In China, colorectal cancer ranked the third highest in the incidence rate, while the mortality rate ranked fifth.[2](#ijc32079-bib-0002){ref-type="ref"} The environmental risk factors for colorectal cancer include sedentary living, staying up all night, poor eating habits and so on.[3](#ijc32079-bib-0003){ref-type="ref"}, [4](#ijc32079-bib-0004){ref-type="ref"}, [5](#ijc32079-bib-0005){ref-type="ref"} However, despite exposure to the same harmful environmental factors, the occurrence of colorectal cancer varies from person to person, indicating that the occurrence of colorectal cancer is a result of a combination of environmental and genetic factors. Previous studies have found that colorectal cancer patients with a family history of the disease could have twice the risk of those without a family history.[6](#ijc32079-bib-0006){ref-type="ref"}, [7](#ijc32079-bib-0007){ref-type="ref"} They also found that genetic factors accounted for 35% of the risk of developing sporadic colorectal cancer. Additionally, many case--control studies showed that genetic variations were closely related to colorectal cancer, among which single‐nucleotide polymorphisms (SNPs) were one of the most common type.[8](#ijc32079-bib-0008){ref-type="ref"}, [9](#ijc32079-bib-0009){ref-type="ref"}

Recently, multiple genome‐wide association studies (GWASs) have reported several genes or loci associated with colorectal cancer susceptibility.[10](#ijc32079-bib-0010){ref-type="ref"}, [11](#ijc32079-bib-0011){ref-type="ref"}, [12](#ijc32079-bib-0012){ref-type="ref"}, [13](#ijc32079-bib-0013){ref-type="ref"}, [14](#ijc32079-bib-0014){ref-type="ref"} For the Asian population, SNP rs7758229 located in the chromosome 6q26‐q27 region was the first discovered to be associated with the risk of distant colorectal cancer in the Japanese population.[15](#ijc32079-bib-0015){ref-type="ref"} However, in our previous validation study within the Chinese population, we found that rs7758229 showed no relationship with colorectal cancer risk.[16](#ijc32079-bib-0016){ref-type="ref"} We attributed the possible causes of inconsistencies to differences in the genetic background and minor allele frequency (MAF) among races. Therefore, it is reasonable that different effects of SNPs on disease exist in different races. The effect of rs7758229 on the Japanese population found by GWASs might only be the chain embodiment of the adjacent pathogenic sites, and the real pathogenic sites might be located in other sites of the chromosome 6q26‐q27 region.[17](#ijc32079-bib-0017){ref-type="ref"}, [18](#ijc32079-bib-0018){ref-type="ref"}, [19](#ijc32079-bib-0019){ref-type="ref"}, [20](#ijc32079-bib-0020){ref-type="ref"} Therefore, we proposed that there could be genetic variation associated with susceptibility to colorectal cancer in this region.

Here, we conducted a comprehensive analysis on the chromosome 6q26‐q27 region to further clarify the potential causal variants in this region related to colorectal cancer risk. our study will provide important clues to screen patients with high colorectal cancer risk, implementing individual treatment and assessing the prognosis of colorectal cancer patients in the future, as well as further elucidating the pathogenesis of colorectal cancer.

Methods {#ijc32079-sec-0004}
=======

Patients or participants {#ijc32079-sec-0005}
------------------------

All subjects of our study were from the Chinese Han individuals. A case--control study was performed with enrolling 1,147 colorectal cancer cases and 1,203 controls. All cases were diagnosed and confirmed by pathology at The First Affiliated Hospital and Nanjing First Hospital of Nanjing Medical University, without other tumor history. The controls matched age and sex to cases were randomly selected among the population for physical examination in the same geographical region without genetically related to the cases. Details of the study participants have been demonstrated previously.[21](#ijc32079-bib-0021){ref-type="ref"} All subjects recruited for the study signed informed consent and provided 5 ml of peripheral blood. A consolidated face‐to‐face questionnaire survey was used for the case and control groups. All subjects who had smoked daily for over 1 year were considered smokers, and the remaining subjects were considered nonsmokers. Individuals who had consumed one or more glasses of alcohol weekly for at least 1 year were considered drinkers, and the remaining subjects were considered non‐drinkers. The study protocol was performed in accordance with the Institutional Review Board of Nanjing Medical University.

Selection strategies of SNPs {#ijc32079-sec-0006}
----------------------------

Based on the genotyping data of CHB and JPT population from1000 Genomes Project Database (<http://www.1000genomes.org>), the strategies of selecting SNPs were as follows: (i) SNPs locating in the chromosome 6q26‐q27 region (GRCh37/hg19, <http://genome.ucsc.edu/>); (ii) SNPs with MAF \> 0.05, *p* value of Hardy--Weinberg Equilibrium \>0.05 and call rate \> 95%; (iii) tag SNPs using the Haploview 4.0 software according to linkage disequilibrium (LD) of *r* [2](#ijc32079-bib-0002){ref-type="ref"} \> 0.6; (iv) SNPs with high function scores referring to the online tools of HaploReg v4.1 (<http://archive.broadinstitute.org/mammals/haploreg/haploreg.php>).

TaqMan genotyping {#ijc32079-sec-0007}
-----------------

We derived genomic DNA from EDTA‐venous blood by the Qiagen Blood Kit (Qiagen). The samples were genotyped by TaqMan assays with the ABI 7900HT Real‐time PCR System (Applied Biosystems). All the primers and probes for the TaqMan assay are listed in Supporting Information Table [S1](#ijc32079-supitem-0001){ref-type="supplementary-material"}. The reaction conditions of the assay were followed by manual. After the reaction was completed, the fluorescence was detected, and the amplification curve and genotyping data were derived by Sequence Detection System version 2.4 (SDS 2.4) software. Two samples of 1,203 controls failed to be genotyped due to the quality of them.

Luciferase activity {#ijc32079-sec-0008}
-------------------

The 1,000‐bp‐containing rs420038 A or G alleles of the enhancer sequence and *SLC22A3* promoter region were synthesized. Both of them were cloned into the pGL3‐basic Vector (Promega) by the *NheI* and *XhoI* restriction sites and confirmed by DNA sequencing. In luciferase assays, HCT116 and SW620 cells were plated onto 24‐well plates and transfected with plasmids above by Lipofectamine 2000 (Invitrogen). As an internal reference, 10 ng pRL‐SV40, which contained the Renilla luciferase gene, was co‐transfected with all plasmids. All of the transfections were performed in triplicate. After transfection for 24 h, the cells were collected for luciferase activity measurement using a Dual‐Luciferase Reporter Assay System (Promega). The relative luciferase activity was compared by the two‐sided *t*‐test after normalized to Renilla luciferase.

Quantitative RT--PCR {#ijc32079-sec-0009}
--------------------

Four cell lines of colorectal cancer (i.e., HT29, DLD1, HCT116 and SW620) were purchased from Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China) and maintained under standard conditions. Authenticity of any human cell lines used in our study has been proven by DNA profiling. Cell line authentication was conducted by the Genetic Testing Biotechnology Corporation (Suzhou, China) and the KeyCen BioTech (Nanjing, China) by short tandem repeat (STR) markers. The authentication results were compared to those of the American Type Culture Collections (ATCC) cell bank. No mycoplasma contamination was detected. Total RNA was isolated from cells and tissue samples by TRIzol (Invitrogen) and was quantified by ultraviolet spectrometry. The relative mRNA expression level of *SLC22A3* and the internal reference genes were detected using the ABI 7900 Real‐Time PCR system (Applied Biosystems). ACTINB was selected as endogenous control using geNorm39. The primer sets designed are shown in Supporting Information Table [S1](#ijc32079-supitem-0001){ref-type="supplementary-material"}.

Western blotting {#ijc32079-sec-0010}
----------------

Western blot assays were performed as standard procedures. The primary antibodies used were monoclonal rabbit anti‐SLC22A3 (1:1,000; ab151698; Abcam) and rabbit anti‐b‐actin (1:1,000; 13E5; Cell Signaling Technology). The secondary antibody was anti‐rabbit HRP (1:1,000; BS13278, Bioworld Technology). The immune complexes were detected by enhanced chemiluminescence (Cell Signaling Technology).

Construction and transfection of overexpression and knockdown of *SLC22A3* {#ijc32079-sec-0011}
--------------------------------------------------------------------------

To overexpress and knock down of *SLC22A3* in colorectal cancer cells, one *SLC22A3* cDNA was cloned into pEGFP‐C1 Vector (Clontech) by *XhoI/BamHI* restriction sites and confirmed by DNA sequencing. Two independent siRNAs were synthesized. The sequences of two siRNAs are shown in Supporting Information Table [S1](#ijc32079-supitem-0001){ref-type="supplementary-material"}. The effect of *SLC22A3* overexpression and knockdown was determined by quantitative RT--PCR and Western blotting. Lipofectamine 2000 transfection reagent (Invitrogen) was used in transfection. All the plasmid sequences were confirmed by sequencing.

Cell proliferation and cell death assays {#ijc32079-sec-0012}
----------------------------------------

Cell Counting Kit‐8 (CCK‐8; Dojindo) was performed at various time intervals by an Infinite M200 spectrophotometer (Tecan). The absorbance at an optical density of 450 nm represented cell proliferation. The cell cycle assay was performed using a FACS Calibur flow cytometer (Beckman Coulter) when cells were fixed with 75% ethyl alcohol and stained with propidium iodide. Flow cytometry was adopted to detect cell apoptosis when the cells were dealt with the Annexin V‐FITC apoptosis detection kit (Invitrogen). All of our experiments were independently conducted three times at least, and the data were expressed as means ± standard deviation. Statistical comparisons were analyzed using two‐sided *t*‐test.

Statistical analysis {#ijc32079-sec-0013}
--------------------

The association between the selected SNP and colorectal cancer risk was evaluated in the additive, dominant and recessive model after adjusted for age and sex by logistic regression. We assessed the correlations between each SNP genotype and the mRNA expression level through the analysis of linear model in expression quantitative trait loci (eQTL) analysis. The software of SAS 9.4 (SAS Institute) and Stata 10.0 (StataCorp LP) were both used.

Results {#ijc32079-sec-0014}
=======

SNPs selection from chromosome 6q26‐q27region {#ijc32079-sec-0015}
---------------------------------------------

Supporting Information Table [S2](#ijc32079-supitem-0001){ref-type="supplementary-material"} summarized the characteristics of the subjects included in our study. The SNP selection process was shown in Figure [1](#ijc32079-fig-0001){ref-type="fig"}. Shortly, a total of 6,371 SNPs were located in chromosome 6q26‐q27 region, and 923 of them passed the standard quality control. Next, with additional LD of *r* ^2^ \> 0.6, 14 tag SNPs were screened for further analysis (Supporting Information Table [S3](#ijc32079-supitem-0001){ref-type="supplementary-material"}).

![The flow chart of selecting 14 potential functional SNPs in the chromosome 6q26‐q27. \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](IJC-145-154-g001){#ijc32079-fig-0001}

Evaluation association of candidate SNPs with colorectal cancer risk {#ijc32079-sec-0016}
--------------------------------------------------------------------

Next, we applied logistic regression to analyze the association between the selected SNPs and risk of colorectal cancer. As shown in Table [1](#ijc32079-tbl-0001){ref-type="table"} **,** the distribution frequencies of the tag SNP genotypes of the control group were in accordance with HWE (*p* \> 0.05), except for SNP rs2221750. Therefore, we removed it in the later evaluation. For rs420038, the GA/AA genotype was associated with a lower risk of colorectal cancer (adjusted OR = 0.79; 95% CI = 0.67--0.94; *p* = 0.007) than the GG genotype; for rs9456537, the TT/CT genotype was 19% higher than the CC genotype colorectal cancer (adjusted OR = 1.19; 95% CI = 1.01--1.40; *p* = 0.043); for rs2048328, compared to the GG genotype, the GA/AA genotype decreased the colorectal cancer risk (adjusted OR = 0.81; 95% CI = 0.69--0.96; *p* = 0.013); for rs3124784, compared to the GG genotype, the AA/GA genotype increased the risk of colorectal cancer (adjusted OR = 1.29; 95% CI = 1.07--1.56; *p* = 0.009); for rs7765803, the mutant genotype reduced the risk of colorectal cancer (adjusted OR = 0.77; 95% CI = 0.64--0.91; *p* = 0.003). Additionally, we did not find that the remaining 8 SNPs were associated with the colorectal cancer risk (*p* \> 0.05).

###### 

Association between the 14 selected SNPs and colorectal cancer risk

  SNPs            MAF (1KG/case/control)   *p* ~HWE~   MM/MN/NN      OR~additive~ (95% CI)[a](#ijc32079-note-0004){ref-type="fn"}   *p* [a](#ijc32079-note-0004){ref-type="fn"}   *p* ~FDR~   OR~dominant~ (95% CI)[a](#ijc32079-note-0004){ref-type="fn"}   *p* [a](#ijc32079-note-0004){ref-type="fn"}   *p* ~FDR~   OR~recessive~ (95% CI)[a](#ijc32079-note-0004){ref-type="fn"}   *p* [a](#ijc32079-note-0004){ref-type="fn"}   *p* ~FDR~   
  --------------- ------------------------ ----------- ------------- -------------------------------------------------------------- --------------------------------------------- ----------- -------------------------------------------------------------- --------------------------------------------- ----------- --------------------------------------------------------------- --------------------------------------------- ----------- -----------
  rs668871        0.263/0.346/0.365        0.950       144/503/497   159/559/483                                                    0.92 (0.82--1.03)                             0.165       0.230                                                          0.88 (0.74--1.03)                             0.114       0.228                                                           0.94 (0.74--1.20)                             0.618       0.808
  rs675162        0.335/0.384/0.408        0.591       161/558/428   195/590/416                                                    0.90 (0.80--1.01)                             0.081       0.142                                                          0.89 (0.75--1.05)                             0.177       0.275                                                           0.84 (0.67--1.05)                             0.129       0.451
  **rs420038**    0.371/0.374/0.410        0.311       163/532/452   193/599/409                                                    0.86 (0.76--0.97)                             0.011       **0.037**                                                      0.79 (0.67--0.94)                             0.007       **0.040**                                                       0.86 (0.69--1.08)                             0.196       0.458
  rs2221750       0.196/0.239/0.209        0.011       72/404/671    38/426/737                                                     1.19 (1.04--1.37)                             0.013       **0.037**                                                      1.13 (0.96--1.33)                             0.151       0.264                                                           2.04 (1.36--3.05)                             0.001       **0.007**
  **rs9456537**   0.237/0.256/0.222        0.277       83/421/642    52/429/720                                                     1.21 (1.06--1.39)                             0.005       **0.037**                                                      1.19 (1.01--1.40)                             0.043       **0.121**                                                       1.72 (1.21--2.46)                             0.003       **0.020**
  rs3123636       0.263/0.240/0.252        0.702       71/408/668    73/458/670                                                     0.94 (0.82--1.07)                             0.350       0.408                                                          0.90 (0.77--1.07)                             0.230       0.297                                                           1.02 (0.73--1.43)                             0.922       0.922
  rs2661834       0.351/0.365/0.385        0.180       153/531/463   166/590/443                                                    0.92 (0.81--1.03)                             0.154       0.230                                                          0.87 (0.73--1.02)                             0.088       0.205                                                           0.95 (0.75--1.21)                             0.693       0.808
  rs1810126       0.454/0.445/0.448        0.560       227/566/354   245/583/371                                                    0.99 (0.88--1.11)                             0.856       0.856                                                          1.01 (0.85--1.20)                             0.931       0.931                                                           0.96 (0.78--1.17)                             0.674       0.808
  **rs2048328**   0.345/0.331/0.360        0.287       131/498/518   147/571/482                                                    0.88 (0.78--0.98)                             0.031       0.072                                                          0.81 (0.69--0.96)                             0.013       **0.046**                                                       0.92 (0.71--1.18)                             0.496       0.771
  **rs3124784**   0.155/0.145/0.117        0.126       31/270/846    22/238/941                                                     1.26 (1.07--1.49)                             0.007       **0.037**                                                      1.29 (1.07--1.56)                             0.009       **0.040**                                                       1.47 (0.85--2.57)                             0.171       0.458
  rs1801693       0.485/0.451/0.477        0.773       224/582/337   270/605/326                                                    0.90 (0.80--1.01)                             0.079       0.142                                                          0.90 (0.75--1.07)                             0.233       0.297                                                           0.84 (0.69--1.03)                             0.090       0.418
  **rs7765803**   0.459/0.414/0.451        0.352       208/533/405   236/611/354                                                    0.86 (0.77--0.97)                             0.012       **0.037**                                                      0.77 (0.64--0.91)                             0.003       **0.037**                                                       0.91 (0.74--1.11)                             0.349       0.638
  rs9347438       0.366/0.371/0.381        0.245       159/532/456   164/586/451                                                    0.96 (0.85--1.08)                             0.512       0.551                                                          0.92 (0.77--1.08)                             0.296       0.319                                                           1.02 (0.81--1.29)                             0.856       0.922
  rs1800769       0.418/0.433/0.415        0.552       209/575/363   201/594/406                                                    1.08 (0.96--1.21)                             0.214       0.272                                                          1.10 (0.93--1.31)                             0.271       0.317                                                           1.10 (0.89--1.37)                             0.365       0.638

Logistic regression analysis with adjustment for age and sex. MAF, minor allele frequency; 1KG, the 1,000 Genomes Projects(CHB and JPT); HWE, Hardy--Weinberg equilibrium; M, Mutant allele; N, Wild‐type allele; MM/MN/NN, Additive model; (MM+ MN)/NN, Dominant model; MM/(NN + MN), Recessive model; OR, odds ratio; CI, confidence interval; FDR, false discovery rate.

In addition, we performed eQTL analysis using the genotyping and RNA sequencing data of colorectal cancer from The Cancer Genome Atlas (TCGA) to determine whether these risk SNPS (i.e., rs420038, rs9456537, rs2048328, rs3124784 and rs7765803) were correlated with the expression of their located genes. As shown in Supporting Information Figure [S1](#ijc32079-supitem-0002){ref-type="supplementary-material"}, the eQTL analysis indicated that there was an inverse association of rs420038 with *SLC22A3* expression in normal tissues (*p* = 0.040, Supporting Information Fig. [S1a](#ijc32079-supitem-0002){ref-type="supplementary-material"}) but not in colorectal cancer tissues (*p* = 0.843, Supporting Information Fig. [S1a](#ijc32079-supitem-0002){ref-type="supplementary-material"}), and also rs7765803 with *LPA* expression in normal tissues (*p* = 0.005, Supporting Information Fig. [S1e](#ijc32079-supitem-0002){ref-type="supplementary-material"}) but not in tumor tissues (*p* = 0.241, Supporting Information Fig. [S1e](#ijc32079-supitem-0002){ref-type="supplementary-material"}). Furthermore, we found that *SLC22A3* was widely expressed in various organs (Supporting Information Fig. [S2a](#ijc32079-supitem-0003){ref-type="supplementary-material"}), while *LPA* was specifically expressed in the liver (Supporting Information Fig. [S2b](#ijc32079-supitem-0003){ref-type="supplementary-material"}). Considering the feasibility, we therefore focused on rs420038 in *SLC22A3* for further studies.

Stratified analysis of the association of rs420038 with colorectal cancer risk {#ijc32079-sec-0017}
------------------------------------------------------------------------------

We further conducted a stratified analysis according to the basic characteristics such as age, sex, tumor location, smoking status, drinking status, tumor family history, pathological type, TNM staging and other clinical features. As shown in Supporting Information Tables [S4](#ijc32079-supitem-0001){ref-type="supplementary-material"} and [S5](#ijc32079-supitem-0001){ref-type="supplementary-material"}, individuals with the AA/GA genotype had a lower risk of colorectal cancer than those with the GG genotype when they were at an age equal to or less than 60 years (adjusted OR = 0.64, 95% CI = 0.50--0.81, *p* \< 0.001), male (adjusted OR = 0.69, 95% CI = 0.56--0.87, *p* = 0.001), non‐smokers (adjusted OR = 0.77, 95% CI = 0.62--0.95, *p* = 0.013), drinkers (adjusted OR = 0.68, 95% CI = 0.48--0.96, *p* = 0.028), no family history (adjusted OR = 0.81, 95% CI = 0.67--0.98, *p* = 0.026) and Well/ Medium differentiation (adjusted OR = 0.79, 95% CI = 0.67--0.95, *p* = 0.010).

Potential regulatory effect of rs420038 on *SLC22A3* {#ijc32079-sec-0018}
----------------------------------------------------

We further explored the potential biological molecular mechanisms of rs420038 regulating the transcription of *SLC22A3*. The HaploReg v4.1 functional prediction showed that rs420038 was located in the region of H3K4me1, H3K4me3, H3K27ac and other histone modifications in digestive tract tumors (Supporting Information Table [S6](#ijc32079-supitem-0001){ref-type="supplementary-material"}), suggesting that rs420038 could affect the expression of *SLC22A3* by influencing its promoter activity.

To validate whether different alleles of rs420038 changed the promoter activity of *SLC22A3*, we performed luciferase report assays. As shown in the map of the PGL3‐Basic‐Plasmid (Supporting Information Fig. [S3](#ijc32079-supitem-0004){ref-type="supplementary-material"}), the sequence containing G or A allele of rs420038 was cloned upstream of promoter‐luciferase reporter vector of *SLC22A3* (Supporting Information Table [S7](#ijc32079-supitem-0001){ref-type="supplementary-material"}). We then measured the luciferase activity after transfection, and the results showed that the transcriptional activity of the colorectal cancer cells with the A allele was significantly lower than that of those with the G allele (HCT116: *p* = 0.010; SW620: *p* = 0.030, Fig. [2](#ijc32079-fig-0002){ref-type="fig"}), suggesting that different alleles of rs420038 could alter the transcriptional activity of *SLC22A3*.

![The rs420038 alleles affect the activity of promoter. rs420038 with A or G alleles was cloned upstream of the *SLC22A3* promoter‐luciferase reporter vector. HCT116 and SW620 cells were transiently transfected with each of these constructs and assayed for luciferase activity after 24 h. The P‐value was calculated with two‐sided t‐test. \**p* \< 0.05, \*\* *p* \< 0.01. \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](IJC-145-154-g002){#ijc32079-fig-0002}

Functional exploration of *SLC22A3* in colorectal cancer {#ijc32079-sec-0019}
--------------------------------------------------------

In order to choose proper cell line for the next experiment, four colorectal cancer cells were detected for mRNA expression levels of *SLC22A3* (Fig. [3](#ijc32079-fig-0003){ref-type="fig"} *a*). Next, the *SLC22A3* mRNA expression levels were detected in 94 pairs of colorectal cancer tissues and their adjacent normal tissues, and the results manifested that *SLC22A3* was expressed more highly in tumor tissues than in adjacent normal tissues (*p* \< 0.001, Fig. [3](#ijc32079-fig-0003){ref-type="fig"} *b*), a finding that was consistent with the data from the independent TCGA data comprising RNA‐Seq of 50 paired colorectal tissues (*p* \< 0.001, Fig. [3](#ijc32079-fig-0003){ref-type="fig"} *c*). Moreover, the data from the TCGA data consisting of 644 colorectal cancer tumor tissues and 51 normal tissues showed that *SLC22A3* was highly expressed in tumor tissues (Fig. [3](#ijc32079-fig-0003){ref-type="fig"} *d*). Results were also demonstrated in the subgroups of the colon and rectum (Supporting Information Fig. [S4](#ijc32079-supitem-0005){ref-type="supplementary-material"}). The TCGA data mentioned was up to June, 2016.

![Expression of *SLC22A3* in colorectal cancer cell lines and clinical specimens. (*a*) The *SLC22A3* mRNA expression levels in four colorectal cancer cell lines. (*b*) The *SLC22A3* mRNA expression levels were estimated in 94 pairs of colorectal cancer tissues (tumor) and their adjacent normal tissues (normal). The P value was calculated using the Wilcoxon matched‐pairs signed‐rank test. (*c*) The *SLC22A3* mRNA expression levels were analyzed in paired colorectal tissues from 50 subjects from TCGA data (up to June, 2016). The P‐values were determined using the paired t‐test. (*d*) The *SLC22A3* mRNA expression levels were analyzed in unpaired colorectal tissues of 644 cancer tissues and 51 normal tissues from TCGA data (up to June, 2016). The P‐values were determined using the unpaired t‐test. \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](IJC-145-154-g003){#ijc32079-fig-0003}

To explore the biological function of *SLC22A3* in colorectal cancer, we transfected *SLC22A3* overexpression and siRNA knockdown vectors into DLD1 and SW620 cells, respectively (Supporting Information Fig. [S5](#ijc32079-supitem-0006){ref-type="supplementary-material"})**.** As shown in Figure [4](#ijc32079-fig-0004){ref-type="fig"} *a*, overexpression of *SLC22A3* promoted proliferation (*p* \< 0.05), whereas knockdown of *SLC22A3* suppressed cellular growth (*p* \< 0.05). Moreover, *SLC22A3* overexpression significantly enhanced the migration and invasion ability of colorectal cancer, whereas knockdown of *SLC22A3* exhibited the opposite results (Fig. [4](#ijc32079-fig-0004){ref-type="fig"} *b*). The further cell cycle and apoptosis were analyzed. With *SLC22A3* knockdown, the progression of SW620 cells was arrested in the G1 phase compared to that in control cells, while the overexpression of *SLC22A3* reduced the number of DLD1 cells in G1 phase compared to that in control cells (Fig. [5](#ijc32079-fig-0005){ref-type="fig"} *a*). Moreover, overexpression of *SLC22A3* resulted in a decrease in DLD1 cell apoptosis compared to that in the control group, without a significant difference, but the finding was consistent with the trend that knockdown of *SLC22A3* resulted in an increase in SW620 cell apoptosis compared to that in the control group (Fig. [5](#ijc32079-fig-0005){ref-type="fig"} *b*).

![Roles of *SLC22A3* in regulating colorectal cancer cell growth, migration and invasion. (*a*) Cell proliferation of DLD1 and SW620 cells was measured by the CCK8 assay (OD450 absorbance). (*b*) Transwell migration assay and Matrigel invasion assay. Representative photographs (upper) and quantification (lower) are shown. Columns: average of three independent experiments, \**p* \< 0.05, \*\**p* \< 0.01, original magnification, ×200. \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](IJC-145-154-g004){#ijc32079-fig-0004}

![The effects of *SLC22A3* overexpression or knockdown on the apoptosis and cell cycle of colorectal cancer cell lines. (*a*) Representative results of the cell cycle of DLD1 and SW620 cells transfected with the *SLC22A3* overexpression or knockdown vectors. The cell cycle was analyzed by flow cytometry. Experiments were performed in triplicate and repeated three times. The data are expressed as the means and SD from three replicate samples, and the statistical comparisons were analyzed by two‐sided t‐test. (*b*) Effects of *SLC22A3* overexpression or knockdown on the apoptosis of DLD1 and SW620 cells. The cells transfected with the *SLC22A3* overexpression or knockdown vectors were stained and detected by flow cytometry. The apoptosis rates are expressed as the means and SD of triplicate samples. The P value was calculated by two‐sided t‐test. LR, early apoptotic cells; UR, terminal apoptotic cells, \**p* \< 0.05, \*\**p* \< 0.01. \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](IJC-145-154-g005){#ijc32079-fig-0005}

Discussion {#ijc32079-sec-0020}
==========

SNP rs420038 in the chromosome 6q26‐q27 region was first identified as a novel susceptibility locus for colorectal cancer risk in the Chinese population. compared to the GG genotype, the GA/AA genotype contributed to the reduction in colorectal cancer risk, especially in the subgroups of age equal to or less than 60 years, male gender, non‐smoking, drinking and no family history of cancer.

Many studies have indicated that stress hormones were associated with cancer risk and progression,[22](#ijc32079-bib-0022){ref-type="ref"}, [23](#ijc32079-bib-0023){ref-type="ref"} and *SLC22A3* was associated with the transportation and reuptake of norepinephrine.[24](#ijc32079-bib-0024){ref-type="ref"}, [25](#ijc32079-bib-0025){ref-type="ref"}, [26](#ijc32079-bib-0026){ref-type="ref"} The group of youngers or men may suffer a more stressful life due to various kinds of pressure from family or the society, where norepinephrine would be more generated. In this condition, the inhibition of *SLC22A3* in individuals with A allele would appear more obvious protective effect. However, as generally accepted, the mechanism of the oncogenesis, especially colorectal cancer, is a comprehensive combination of multiple risk factors including environmental conditions, dietary habits and genetic predispositions.[27](#ijc32079-bib-0027){ref-type="ref"} The protective effect observed in subgroups of the ones who never smoke or ever drink seems contradictory and interesting. It is supposed that the toxic substances from tobacco and alcohol are transported or metabolized by many other enzymes such as *CYP1A1*, except the transporter *SLC22A3*. On the other hand, it\'s maybe only a result of the limitation of the size of our samples. The reasons above may explain the statistical significance found in the subgroup of no family history in a certain degree. In a word, it needs further investigation with a larger sample size.

In our study, we carried out functional annotation of the 923 SNPs in the websites of HaploReg v4.1 according to linkage disequilibrium (LD) of *r* ^2^ \> 0.6. In total, 14 tag SNPs were selected for the after study. Subsequently, rs420038, rs9456537, rs2048328, rs3124784 and rs7765803 were associated with the risk of colorectal cancer. Next, eQTL analysis revealed that the intron rs420038 and exon rs7765803 had effects on the mRNA levels of *SLC22A3* and *LPA*, respectively, and the other three loci did not affect their gene expression. The results may be explained by the limitations of the sample size and lack of two‐phase validation. In addition, we cannot rule out that these sites may induce the development of tumors by changing the amino acid types to affect the structure and function of proteins. Moreover, we did not investigate rs7765803 because of the inconsistent trend of effects that CC, CG and GG genotypes of rs7765803 exerted on the expression of *LPA*, and *LPA* was mainly researched in the development of coronary heart disease with very low expression level in intestinal tissue.

Interestingly, when reviewing the 923 variants, we found all the 6 missenses were located at gene of *LPA*. The SIFT or PolyPhen2 predictions (<http://sift.jcvi.org/>, <http://genetics.bwh.harvard.edu/pph2>/) of them are shown in the Supporting Information Table [S8](#ijc32079-supitem-0001){ref-type="supplementary-material"}. The results showed that rs1801693, rs3124784 and rs3798220 would be probably to affect the protein SLC22A3. On the other hand, we found that *SLC22A3* was widely expressed in various organs (Supporting Information Fig. [S2a](#ijc32079-supitem-0003){ref-type="supplementary-material"}), while *LPA* was mainly expressed in the liver with very low expression in other organs. (Supporting Information Fig. [S2b](#ijc32079-supitem-0003){ref-type="supplementary-material"}). Additionally, the eQTL analysis determined that rs420038 and rs7765803 were related with gene expression. Considering hard detection of Lp (a) encoded by *LPA* in colorectal tissues and cells, we thus chose rs420038 of *SLC22A3* as the study object in a further study.

*SLC22A3* is a gene in the chromosome 6q26‐q27 region. It encodes a protein of the solute carrier family 22 family that might play a crucial role in the occurrence and development of colorectal cancer. Functional annotations have suggested that rs420038 may affect the expression of *SLC22A3* by influencing its promoter activity, a finding that was verified in a reporter gene assay. Consequently, the contribution of rs420038 to colorectal cancer development may result from its alteration of the transcriptional activity of *SLC22A3*. We queried available ENCODE data for potential regulatory elements. It was predicted that rs420038 played a role in regulatory chromatin states in colon and rectal smooth muscle cell lines. Further evidence from proteins bound by ChIP (ENCODE) suggested that rs420038 was associated with the binding ability with transcription factor TCTF in HMEC, HeLa‐S3 and NHEK cell lines(<http://genome.ucsc.edu/cgi-bin/hgTracks?db=hg19&lastVirtModeType=default&lastVirtModeExtraState=&virtModeType=default&virtMode=0&nonVirtPosition=&position=chr6%3A160807898%2D160808398&hgsid=699125323_iXYILyRGcEoALa7an00S4kv25z1f>). Further investigation about the internal mechanism would be expected by other researchers in the future. *SLC22A3*, a multispecific organic cation transporter, participates in complex metabolic processes *in vivo*, including transport, inactivation and excretion of various endogenous and exogenous carcinogens.[28](#ijc32079-bib-0028){ref-type="ref"}, [29](#ijc32079-bib-0029){ref-type="ref"}, [30](#ijc32079-bib-0030){ref-type="ref"} It has been reported that the protein can not only transport antitumor drugs such as oxaliplatin and irinotecan,[26](#ijc32079-bib-0026){ref-type="ref"}, [31](#ijc32079-bib-0031){ref-type="ref"}, [32](#ijc32079-bib-0032){ref-type="ref"}, [33](#ijc32079-bib-0033){ref-type="ref"} but also is associated with some endogenous substances, e.g., dopamine, epinephrine, norepinephrine, histamine, and 5‐hydroxytryptamine.[19](#ijc32079-bib-0019){ref-type="ref"}, [29](#ijc32079-bib-0029){ref-type="ref"}, [34](#ijc32079-bib-0034){ref-type="ref"} Norepinephrine and adrenergic receptor signaling pathways were reported to be associated with the development and progression of colorectal cancer. Yokoo *et al*. showed that the transporter played a significant role in oxaliplatin‐induced killing of colorectal cancer cells.[31](#ijc32079-bib-0031){ref-type="ref"} Mohelnikova‐Duchonova *et al*. found that the expression of *SLC22A3* in 32 pancreatic cancer tissues was significantly higher than that in the corresponding normal tissues. And combined with prognostic data analysis, patients with a high expression of *SLC22A3* showed longer overall survival when receiving the treatment of nucleotide analogs.[35](#ijc32079-bib-0035){ref-type="ref"} However, there is no study exploring the relationship between *SLC22A3* and the occurrence, development or drug sensitivity of colorectal cancer. In our study, we found that mRNA expression level of *SLC22A3* was higher in the colorectal cancer tissues than that in the corresponding adjacent normal tissues. However, there is a limitation that we could not find a correlation of *SLC22A3* protein with the mRNA level by linear correlation analysis since the matched samples for mRNA and protein were not acquired.

Moreover, our *in vitro* experiments indicated that the overexpression of *SLC22A3* notably promoted cell proliferation and increased the ability of migration and invasion, whereas the knockdown of *SLC22A3* showed opposite results. However, no significant difference was found regarding the overexpression of *SLC22A3* resulting in a decrease in DLD1 cell apoptosis compared to the control group, but a consistent trend was demonstrated that the knockdown of *SLC22A3* resulted in an increase in SW620 cell apoptosis compared to that in the control group. Additional experiments in multiple colorectal cancer cells are required to verify the results.

In our research, the patients received oxaliplatin‐ or irinotecan‐based chemotherapy after operating. It is regrettable that we have not acquired all the survival information of the individuals included since the follow‐up time of some cases are very short, even less than 6 months. It\'s a limitation of our study. However, we will continue and strengthen postoperative observation and regularly follow up to obtain the complete information about the survival in the future study. If there was an association of our studied SNPs with disease‐free survival of the patients through survival analysis, then additional experiments involved anticancer drugs such as oxaliplatin or irinotecan would be conceived and designed.

In conclusion, we identified a novel susceptibility locus, rs420038, for colorectal cancer located in the *SLC22A3* gene in the Chinese population. SNP rs420038 A allele may involve in downregulating the expression of *SLC22A3*, which plays a role in decreasing colorectal cancer risk. Further investigation is needed to elucidate the underlying molecular mechanism of *SLC22A3* in colorectal cancer.
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